Andy Chen
Stock Analyst at Wolfe Research
(4.48)
# 880
Out of 5,182 analysts
46
Total ratings
60%
Success rate
22.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Initiates: Outperform | $7 | $1.95 | +258.97% | 1 | Apr 9, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $48 | $12.86 | +273.25% | 1 | Apr 9, 2026 | |
| DNTH Dianthus Therapeutics | Initiates: Outperform | $98 | $83.67 | +17.13% | 1 | Apr 9, 2026 | |
| PHVS Pharvaris | Initiates: Outperform | $42 | $28.22 | +48.83% | 1 | Apr 9, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $12 → $24 | $16.66 | +44.06% | 4 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $37.11 | +137.13% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $85.37 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $26.99 | +85.25% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $83.85 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $430.14 | +27.40% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $775.03 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $13.20 | - | 3 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $40.99 | - | 1 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Peer Perform | n/a | $302.11 | - | 3 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $69.71 | -29.71% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $21.07 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $66.11 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $38.15 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $73.99 | -72.97% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.01 | +5.50% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $97.74 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $33.23 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $516.69 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.61 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $71.78 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $52.06 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.77 | -38.78% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $134.94 | -68.88% | 1 | Feb 15, 2024 |
Palisade Bio
Apr 9, 2026
Initiates: Outperform
Price Target: $7
Current: $1.95
Upside: +258.97%
Avalo Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $48
Current: $12.86
Upside: +273.25%
Dianthus Therapeutics
Apr 9, 2026
Initiates: Outperform
Price Target: $98
Current: $83.67
Upside: +17.13%
Pharvaris
Apr 9, 2026
Initiates: Outperform
Price Target: $42
Current: $28.22
Upside: +48.83%
MoonLake Immunotherapeutics
Mar 23, 2026
Upgrades: Outperform
Price Target: $12 → $24
Current: $16.66
Upside: +44.06%
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $37.11
Upside: +137.13%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $85.37
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $26.99
Upside: +85.25%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $83.85
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $430.14
Upside: +27.40%
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $775.03
Upside: -
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.20
Upside: -
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $40.99
Upside: -
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $302.11
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $69.71
Upside: -29.71%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $21.07
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $66.11
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $38.15
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $73.99
Upside: -72.97%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $18.01
Upside: +5.50%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $97.74
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $33.23
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $516.69
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.61
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $71.78
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $52.06
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $27.77
Upside: -38.78%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $134.94
Upside: -68.88%